Childhood Cancer Survival Rates

Childhood cancer survival rates have risen so far that cancer is now curable in most children who are diagnosed accurately and treated on a modern protocol. Acute lymphoblastic leukaemia, the most common childhood cancer, has moved from a disease that killed most children to one that eight or nine in ten survive in leading centres. The decisive factors are early suspicion, precise genetic diagnosis, risk-adapted treatment and strong supportive care.

Dr. Arun Singh Danewa, Senior Consultant – Pediatric-Haemato-Oncology & Bone Marrow Transplant (Unit II), Artemis Hospitals, Gurugram, India, framed his masterclass around that shift: from despair to durable survival. His message to doctors across Africa was practical. The tools that produced the gains are known, most of the drugs are old and widely available, and the gap between survival in the West and survival in low-resource settings is largely a gap in diagnosis, stratification and supportive care.

This guide gives the full picture. Three companion articles go deeper: how to recognise and diagnose cancer in a child, childhood leukaemia treatment, targeted therapy, CAR T-cell therapy and their cost, and solid tumours in children, from brain tumours and neuroblastoma to Wilms tumour and limb-saving bone surgery.

Why childhood cancer needs a paediatric oncologist

Childhood cancer needs a paediatric oncologist because a child is not a small adult. A child with a heart problem sees a paediatric cardiologist, and a child with a neurological problem sees a paediatric neurologist; Dr. Danewa argues that cancer should follow the same logic. He gives three reasons the principles of adult oncology cannot simply be scaled down.

1. The biology is different. The cancers that arise in children are, for the most part, different diseases from those in adults, with different genetics and different behaviour.
2. Doses and protocols are different. Even where a cancer occurs in both age groups, the treatment protocol for a child differs substantially.
3. The goal is different. In older adults, oncology often accepts palliation or five to six years of control, and tolerates side effects accordingly. A child has a whole life ahead. The aim is lifelong, healthy survival, which changes how much toxicity is acceptable and how long-term effects are weighed.

The paediatric oncologist also coordinates the team. In brain tumours, for example, the neurosurgeon and the radiation oncologist do much of the definitive work, but Dr. Danewa describes the paediatric oncologist as the conductor of that orchestra: deciding when chemotherapy should accompany radiotherapy, when targeted therapy has a place, and in what sequence the treatments should come.

Types of childhood cancer

Children develop a distinct set of cancers: leukaemias, lymphomas, brain tumours and solid tumours such as neuroblastoma, Wilms tumour, retinoblastoma and bone sarcomas. In Dr. Danewa's description, travelling from head to toe:

What is absent from the list matters as much. There is no lung cancer, no prostate cancer and no multiple myeloma. Those are adult diseases, which is the clearest illustration of why the two specialties diverge.

Childhood cancers are a small share of all cancers, but they are not rare in a paediatric clinic. Leukaemia is the largest group: in Dr. Danewa's estimate, of every ten children in a paediatric oncology clinic, three or four have leukaemia. Brain tumours are the most common solid tumours. Neuroblastoma is the most common tumour in the abdomen and Wilms tumour the second.

Childhood cancer survival rates by cancer type

Survival rates for childhood cancer range from about 90% for ALL in Western data to under 2% at five years for DIPG. They show both how far the field has come and where it still struggles.

AML sits between these extremes. Dr. Danewa described it as a little behind ALL. Long-term survival in childhood AML is around 60 to 70% in well-resourced centres, well below the figures now achieved in ALL.

Why childhood cancer survival has improved

The gains did not come from a single breakthrough. In ALL, the core chemotherapy has barely changed since 1970; what changed is how it is used. Four forces stand out in Dr. Danewa's account, and they now run through every childhood cancer.

• Biology and risk stratification. Flow cytometry (which reads the markers on the cancer cell surface), cytogenetics (examination of the chromosomes) and next-generation sequencing (NGS, which reads many genes at once) place each cancer in a risk group, so that treatment intensity follows the disease: enough to cure, without needless toxicity.
• Supportive care. Better antibiotics and infection management mean fewer children die of complications during treatment.
• Less long-term harm. Treatments that damaged growing children, such as routine brain radiotherapy in ALL, have been narrowed to the few who need them.
• Precision drugs and cellular therapy. Targeted drugs aimed at markers on the cancer cell, and CAR T-cell therapy, which re-engineers a child's own immune cells, now rescue many children whose cancer returns.

In the solid tumours the same principles show up as genetic profiling of brain tumours, targeted pills for gliomas, anti-GD2 therapy for neuroblastoma, and protocols that adapt treatment to each tumour's biology. The leukaemia article traces the ALL story from 1948 to today, and the solid tumours article sets out each tumour in detail.

The survival gap: the West, India and Africa

Dr. Danewa was direct about the gap. Western centres report around 90% survival in ALL. Leading Indian centres, by his account, reach 80 to 85%. In parts of Africa, he estimated, survival may be as low as 40 to 50%. His argument is that joint work, communication and teaching between doctors on both continents can lift it to 80 to 85% and eventually to 90 to 95%.

The constraints are real and they are not unique to Africa. When a doctor from Kenya raised the shortage of cancer infrastructure outside big cities and the very high cost of treatment, Dr. Danewa agreed that India faces many of the same problems. His answer was local solutions: generic medicines as they arrive, and better supportive care.

Diagnose centrally, treat close to home

The model Dr. Danewa proposes rests on a simple observation: the expensive and specialised part of childhood cancer care is concentrated at the start. Accurate diagnosis, genetic testing and risk stratification require flow cytometry, cytogenetics and NGS, which many hospitals lack. Most of the chemotherapy that follows is available everywhere.

So a child can be diagnosed and stratified at a specialist centre, start the initial phase of treatment there, and then return home with a written protocol to complete treatment under the local doctor. Where a family cannot travel, the genetic testing alone can be arranged so that the treating doctor knows from the outset whether the leukaemia needs standard-risk or high-risk therapy. Dr. Danewa offered to keep discussing patients with their local doctors after they return, and stressed that one lecture or one consultation is not enough: the collaboration has to be continuous.

Surgery fits the same pattern. Limb salvage surgery for bone cancer, he pointed out, is not especially costly. It needs expertise more than expensive drugs, and amputation should be the last resort when limb salvage is genuinely not possible.

What causes childhood cancer

Parents almost always ask why their child developed cancer. Dr. Danewa's answer is that, in nearly every case, there is no identifiable reason and nothing the family could have avoided: only around 1% of childhood tumours, in his estimate, are familial, and there is no childhood equivalent of smoking or alcohol. The warning signs article sets out what is known about causes and what doctors should look for.

Cost of childhood cancer treatment in India

Dr. Danewa's closing claim was that survival in leading Indian centres is now close to Western results, at around one-tenth of the cost. CAR T-cell therapy is the clearest example: he put the Western price at 2 to 3 crore rupees, against 30 to 40 lakh rupees for India's indigenous CAR T-cell products. Most targeted drugs for leukaemia and lymphoma are affordable in his assessment, while a few, notably blinatumomab and dinutuximab, remain very expensive. The drug-by-drug figures he gave are in the leukaemia treatment and cost article.

The specialty context sits on the oncology hub, and the haematology hub covers related blood disorders. Dr. Danewa's separate masterclass on sickle cell disease and bone marrow transplant covers transplant for that condition in depth. The questions doctors asked in this session, on risk factors, textbooks, targeted therapy costs, transplant and CAR T-cell therapy, are answered in full in the Live Discussion.